Similarly, mutations or deletions in the tumor suppressor, PTEN, which can disinhibit the pathway can sensitize tumors to mTOR inhibition are uncommon in multiple myeloma (30, 31). The gene discussed is MTOR; the disease is plasma cell myeloma.